EXCLUSIVE: Hoth Therapeutics Integrates OpenAI API To Support Drug Development For Aggressive Cancers

Hoth Therapeutics Inc. (NASDAQ:HOTH) on Wednesday announced the deployment of the OpenAI API to support IND-enabling development of HT-KIT, targeting rare and aggressive KIT-driven cancers.

The company integrated an OpenAI-powered API platform into the HT-KIT development workflow to support preclinical data analysis, molecular modeling of KIT-driven pathways, and preparation of regulatory documentation ahead of IND submission.

Hoth Therapeutics’ HT-KIT Results Show Success In Rare Cancers 

HT-KIT achieved over 80% reduction of KIT mRNA/protein across in vitro systems and in vivo models of systemic mastocytosis and gastrointestinal stromal tumors (GIST).

No dose-limiting toxicities observed in the reported preclinical work to date.

In xenograft models, statistically significant tumor-volume reduction by Day 8 was observed, accompanied by apoptotic signaling consistent with KIT pathway knockdown.

GLP-validated bioanalytical methods completed to support pharmacokinetic, biodistribution, and exposure-response analyses for IND.

HT-KIT is advancing toward Investigational New Drug (IND) submission and Phase 1 clinical evaluation, and has received Orphan Drug Designation.

In February, Hoth Therapeutics revealed preclinical data from a glial cell-derived neurotrophic factor (GDNF) study for obesity and metabolic-associated steatotic liver disease.

The head-to-head study showed that GDNF demonstrated superior efficacy over Novo Nordisk A/S’ NVO) Wegovy and Ozempic️ (semaglutide) in key metrics, including weight stabilization, glucose tolerance, liver weight reduction, and adipose tissue control, particularly in female models.

In January, Hoth Therapeutics shared interim results from the open-label pharmacokinetic (PK) cohort of its ongoing CLEER-001 trial evaluating HT-001 in cancer patients receiving EGFR inhibitor therapy.

100% of evaluable patients achieved clinical response by Week 6, accompanied by an approximate 50% reduction in investigator-assessed disease severity (using the ARIGA scale) from baseline.

In September 2025, Hoth Therapeutics shared combined findings from multiple preclinical programs evaluating HT-KIT.

HT-KIT triggered significant tumor cell death in preclinical models of GIST and systemic mastocytosis as early as 24 hours post-treatment, with statistically significant tumor shrinkage observed by day 8.

HOTH Price Action: Hoth Therapeutics stock closed at $0.997 on Tuesday, according to Benzinga Pro data.

Photo by Camilo Concha via Shutterstock